NESS ZIONA, Israel, May 29, 2019 Kadimastem (TASE: KDST), a stem cell-based therapeutic company, announced recently that Yossi Ben Yosef has stepped down as Chief Executive Officer. Rami Epstein has assumed the role of Chief Executive Officer in addition to his current role as member of the Board of Directors. In order to ensure a smooth transition, Ben Yosef will continue with the Company as Honorary President and strategic consultant to the Chief Executive Officer.
"On behalf of the Board of Directors and employees of Kadimastem, I would like to thank Yossi for his contribution to the Company. Under his leadership, Kadimastem has developed a ground-breaking stem cell platform technology and reached advanced stages of human clinical trials with its product for the treatment for ALS, followed by its solution for diabetes," said Eli Opper, Chairman of Kadimastem. "Rami Epstein, our new CEO, has been a Director at Kadimastem and a part of its leadership team for many years. Rami brings with him extensive business experience in biopharma as an entrepreneur, legal advisor and a leader. I look forward to continuing to work with Rami and the talented team at Kadimastem in order to bring treatment to patients and create value for our shareholders."
"I decided to step down from the Company's leadership role after 11 years as a founding partner and CEO," stated Yossi Ben Yosef. "I am honored to have had the privilege to lead such an exceptional Company with a team of researchers who are determined to bring stem cell-based therapies to patients with serious diseases. I wish Rami great success and I am sure he will lead Kadimastem to its future achievements."
Rami Epstein brings many years of experience as an entrepreneur mainly in the biotech, pharmaceutical and high-tech industries. His main focus is on R&D companies, fund raising, M&As and strategic collaborations. Rami is co-founder of BiondVax Pharmaceuticals (Nasdaq: BVXV) and has served as a member of its Board of Directors for many years. Prior to founding BiondVax Rami also co-founded IDgene Pharmaceuticals, and has served as the Company's COO (VP of Operations) and as a member of its Board of Directors. Rami holds a master's degree (LL.M.) in commercial law and intellectual property from King's College, University of London, and a bachelor's degree (LL.B.) in law from the Hebrew University of Jerusalem.